We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. markets closed

GSK plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
40.66-0.14 (-0.34%)
At close: 04:00PM EDT
40.72 +0.06 (+0.15%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close40.80
Open40.96
Bid40.18 x 3200
Ask41.05 x 2200
Day's Range40.49 - 40.97
52 Week Range33.33 - 43.84
Volume5,264,697
Avg. Volume3,616,725
Market Cap83.443B
Beta (5Y Monthly)0.27
PE Ratio (TTM)13.55
EPS (TTM)3.00
Earnings DateN/A
Forward Dividend & Yield1.47 (3.61%)
Ex-Dividend DateFeb 22, 2024
1y Target Est44.10
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
6% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for GSK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • GSK plc
    Analyst Report: GSK plcIn the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • Insider Monkey

    10 Best Weight Loss Drug Stocks to Buy Now

    In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

  • The Wall Street Journal

    Health Care Roundup: Market Talk

    Read about Agilent Technologies, Novartis, Master Style and more in the latest Market Talks covering the Health Care sector.

  • Zacks

    GSK PLC Sponsored ADR (GSK) is Attracting Investor Attention: Here is What You Should Know

    Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.

  • Reuters

    UPDATE 1-U.S. FDA approves Akebia's anemia drug

    The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.

  • Simply Wall St.

    With 83% ownership of the shares, GSK plc (LON:GSK) is heavily dominated by institutional owners

    Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...

  • Insider Monkey

    12 Best Biotech Penny Stocks to Invest In

    In this article, we discuss the 12 best biotech penny stocks to invest in. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Biotech Penny Stocks to Invest In. The past few years have been a topsy-turvy ride for the biotech sector. There was a massive increase in […]

  • Motley Fool

    Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?

    Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

  • The Wall Street Journal

    Pfizer to Raise Around $3.5 Billion From Haleon Shares Sale

    Pfizer is raising around $3.5 billion from the sale of part of its stake in consumer-healthcare business Haleon

  • Bloomberg

    Pfizer Sells $3.5 Billion of Shares in Haleon

    (Bloomberg) -- Pfizer Inc. has sold more than £2.8 billion ($3.5 billion) of shares in Haleon Plc, the first step by the UK consumer health company’s biggest shareholder to reduce its 32% stake. Most Read from BloombergTrump Rules Out Vivek Ramaswamy as Running Mate as He Eyes New TeamApple Is in Talks to Let Google Gemini Power iPhone AI FeaturesNvidia Looks to Extend AI Dominance With New Blackwell ChipsEvergrande’s Alleged $78 Billion Fraud Is Among Biggest EverMusk Says His Ketamine Prescrip

  • The Wall Street Journal

    Now That Two Inhaler Makers Are Capping Patient Costs, Will More Follow?

    AstraZeneca’s move on Monday to cap at $35 the out-of-pocket costs that patients pay for the company’s Symbicort inhaler speaks to the political and regulatory pressure coming to bear on manufacturers of certain commonly used but expensive treatments. The British drugmaker’s shift follows a similar step last month by Boehringer Ingelheim, which sells rival inhalers including Atrovent and Spiriva. Sen. Bernie Sanders, the independent from Vermont, launched an investigation of inhaler prices in January.